• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SYBX

    Synlogic Inc.

    Subscribe to $SYBX
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: synlogictx.com

    Recent Analyst Ratings for Synlogic Inc.

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    See more ratings

    Synlogic Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synlogic Reports Third Quarter 2024 Financial Results

      WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

      11/12/24 4:35:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2024 Financial Results

      WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

      8/8/24 7:00:52 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2024 Financial Results

      CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

      5/14/24 7:00:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

      CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company. Fourth Quarter 2023 Financial Results As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million. Revenue was $2.8 million for the three months ende

      3/19/24 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

      Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU). As a result, Synlogic's management and its Board of Directors have made the decision to evaluate st

      2/8/24 4:15:00 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

      Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting mild-moderate gastrointestinal adverse events CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clini

      2/2/24 12:00:00 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Provides Corporate Update and Outlook for 2024

      - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1 2025 - CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today summarized accomplishments for 2023 and anticipated key milestones for 2024. "We are pleased with the important corporate progress we achieved in 2023 - highlighted by the initiation of our global pivotal Synpheny-3 study evaluating our potentially trans

      1/4/24 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Contract with the Air Force Research Lab

      CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing process to support development of a potential live probiotic product. The grant is an extension of work initiated by Synlogic in 2020 as part of the Air Force Synthetic Biology Challenge with the Massachusetts Institute of Technology (MIT). Synlogic's activities on this project are expected to start in Q1 2024

      12/27/23 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flynn James P was granted 15,000 shares (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:43:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/3/25 4:30:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $2,802 worth of shares (2,107 units at $1.33), decreasing direct ownership by 14% to 13,045 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      2/4/25 5:53:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Head of Finance Dooley Mary Beth sold $111 worth of shares (79 units at $1.40), decreasing direct ownership by 0.52% to 15,152 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      10/30/24 7:21:40 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dooley Mary Beth sold $325 worth of shares (188 units at $1.73), decreasing direct ownership by 1% to 15,231 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/4/24 4:00:48 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Awad Antoine sold $644 worth of shares (372 units at $1.73), decreasing direct ownership by 1% to 33,859 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/4/24 4:00:05 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Flynn James P

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      3/21/24 5:09:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dooley Mary Beth claimed ownership of 15,419 shares (SEC Form 3)

      3 - SYNLOGIC, INC. (0001527599) (Issuer)

      3/21/24 5:10:04 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Flynn James P

      3 - SYNLOGIC, INC. (0001527599) (Issuer)

      3/21/24 5:06:07 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

      – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

      3/29/23 6:40:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

      CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

      1/3/23 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of General Counsel and Corporate Secretary

      CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Brendan St. Amant as General Counsel and Corporate Secretary effective July 1, 2022. "Since joining Synlogic last year, Brendan has been invaluable in his guidance and sound counsel on many complex legal and business issues," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "In his new role, Brendan will continue to provide strong leadership as the company continues its progress towards man

      6/29/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

      Scorpion Therapeutics, Inc. ("Scorpion Therapeutics"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors. Dr. Saha is currently the Chief Executive Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA) ("Centessa") and brings more than 20 years of biopharmaceutical research and development expertise to the role. "We are pleased to welcome Dr. Saha to our Board of Directors," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "His passion for discovering new cancer treatments, coupled with his track record o

      4/4/22 8:00:00 AM ET
      $CNTA
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

      CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. Jensen brings extensive and diversified experience within global pharmaceutical and medical device companies to Synlogic, spanning analytics, financial management, information systems, and operations. "I am delighted to welcome Michael to Synlogic," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Michael has an impressive finance and operati

      3/3/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Appoints Molly Harper as Chief Business Officer

      CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms. Harper will provide strategic leadership to the commercial, corporate development and business development functions, and lead the planning and commercialization of Synlogic's growing pipeline.   "We are thrilled to welcome Molly to Synlogic. Molly's appointment could not come at a better time given our recent encouraging interim analysis data in our PKU program, and our intention to begin a pivotal program in PKU in 2022. Her deep experienc

      9/27/21 6:30:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer and Strengthening of Leadership Team

      CAMBRIDGE, Mass., March 8, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer, Dr. Kurtz will be responsible for portfolio strategy, program leadership, and development of Synlogic's portfolio of Synthetic Biotic medicines, including the company's lead assets, SYNB1618 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria. Dr. Caroline Kurtz Dr. Jamie Austin Daniel Rosan "At Synlogic, we are advancing multiple programs rapidly tow

      3/8/21 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors

      CAMBRIDGE, Mass., Feb. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Lisa Kelly-Croswell to its board of directors. Lisa Kelly-Croswell "We are delighted to welcome Lisa to our Board," said Aoife Brennan, M.B, Ch.B., Synlogic's President and Chief Executive Officer. "Lisa is an exceptional leader with over 25 years of experience across the healthcare spectrum. Her expertise in rapid growth business environments and building high impact teams to drive innovation will be hugely valuable to Synlogic. We are looking forward to learn

      2/10/21 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Outlines Upcoming Clinical Milestones

      CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress. "With three programs in clinical trials, multiple proof of concept opportunities, and a preclinical portfolio advancing rapidly towards the clinic, Synlogic is poised for success with a number of data readouts coming in 2021," said Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer. "2020 was a year we will not forget. Despite the external challenges, the Synlogic team moved our programs forw

      1/11/21 6:30:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synlogic upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

      11/24/21 7:28:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic upgraded by Oppenheimer

      Oppenheimer upgraded Synlogic from Perform to Outperform

      11/24/21 4:55:59 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Synlogic with a new price target

      SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

      11/11/21 5:14:48 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Synlogic with a new price target

      HC Wainwright & Co. reiterated coverage of Synlogic with a rating of Buy and set a new price target of $7.00 from $9.00 previously

      10/13/21 6:16:38 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler reiterated coverage on Synlogic with a new price target

      Piper Sandler reiterated coverage of Synlogic with a rating of Overweight and set a new price target of $9.00 from $7.00 previously

      9/20/21 12:24:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Synlogic with a new price target

      HC Wainwright & Co. reiterated coverage of Synlogic with a rating of Buy and set a new price target of $9.00 from $13.00 previously

      6/28/21 6:08:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JonesTrading initiated coverage on Synlogic with a new price target

      JonesTrading initiated coverage of Synlogic with a rating of Buy and set a new price target of $15.00

      3/18/21 9:13:44 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synlogic Inc.

      10-K - SYNLOGIC, INC. (0001527599) (Filer)

      3/6/25 4:47:33 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Synlogic Inc.

      SCHEDULE 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      2/25/25 4:23:12 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Inc. filed SEC Form 8-K: Leadership Update

      8-K - SYNLOGIC, INC. (0001527599) (Filer)

      2/21/25 4:30:08 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Inc. filed SEC Form 8-K: Leadership Update

      8-K - SYNLOGIC, INC. (0001527599) (Filer)

      1/14/25 5:00:08 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Inc. filed SEC Form 8-K: Leadership Update

      8-K - SYNLOGIC, INC. (0001527599) (Filer)

      12/20/24 8:40:56 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Synlogic Inc.

      S-8 - SYNLOGIC, INC. (0001527599) (Filer)

      11/12/24 4:49:37 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Synlogic Inc.

      S-8 - SYNLOGIC, INC. (0001527599) (Filer)

      11/12/24 4:47:35 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      11/12/24 4:39:21 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      5/16/24 7:44:32 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      4/18/24 11:18:42 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Synlogic Inc.

      SC 13D - SYNLOGIC, INC. (0001527599) (Subject)

      2/16/24 4:44:06 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      2/14/24 3:55:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synlogic Inc. (Amendment)

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      2/14/24 10:56:50 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synlogic Inc. (Amendment)

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      2/9/24 9:49:31 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      10/13/23 4:17:56 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synlogic Inc. (Amendment)

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      10/13/23 3:59:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synlogic Inc. (Amendment)

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      10/10/23 9:09:13 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Synlogic Inc. Financials

    Live finance-specific insights

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

      Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

      12/15/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

      Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

      10/18/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

      – Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – $106.8 million in cash, cash equivalents and short-term investments support projected runway into 2024 – – Conference call and webcast at 8:30 a.m. ET today – CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its pipeline programs. "We look forwa

      8/11/22 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Second Quarter 2022 Conference Call and Webcast

      CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. The press release will be followed by a conference call at 8:30 A.M. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update. To access the webcast, please register here. To access the call by phone, please reg

      7/28/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

      - Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 – - PKU program progressing with Phase 3 readiness activities underway – - $120.5 million in cash, cash equivalents and short-term investments support projected runway into 2024 – - Conference call and webcast at 8:30 a.m. ET today – CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the first quarter ended March 31, 2022 and provided an upda

      5/12/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces First Quarter 2022 Conference Call and Webcast

      CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its first quarter 2022 financial results before the market opens on Thursday, May 12, 2022. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0

      5/5/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

      - Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – - Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2 2022 – - $136.6 million in cash, cash equivalents and marketable securities support projected runway into 2024 – - Conference call and webcast at 8:30 a.m. ET today – CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the fourth quarter and full year endin

      3/17/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

      CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its fourth quarter and full year 2021 financial results before the market opens on Thursday, March 17, 2022. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update. The conference call dial-in numbers are (844) 815-2882 for domestic cal

      3/10/22 7:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

      CAMBRIDGE, Mass., Nov. 2, 2021 /PRNewswire/ -- Synlogic, Inc. ((SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2021 financial results before the market opens on Wednesday, November 10, 2021. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update. The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the

      11/2/21 8:00:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care